Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Co. (UK) Ltd. as Sole Book-Running Manager of Viking Therapeutics’ $24.0M IPO
New York, NY – May 6, 2015 – New York City based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (the “Firm”) announced today that the Firm has represented Laidlaw & CO. (UK) Ltd. as the sole book-running manager of the initial public offering (IPO) of Viking Therapeutics, Inc. (NASDAQ: VKTX). The public offering consisted of 3,000,000 shares of the Company’s common stock at a price to the public of $8.00 per share which resulted in aggregate gross proceeds of $24,000,000 before deducting expenses. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The Sichenzia Ross Friedman Ference LLP team was led by Partners Richard A. Friedman and Stephen A. Cohen.
- Sichenzia Ross Ference LLP Joins Splash Beverage Group, Inc. in Ringing Opening Bell at NYSE - July 29, 2022
- Sichenzia Ross Ference LLP Represents Roth Capital Partners in Public Offering of Common Stock of Crown Electrokinetics Corp. - July 26, 2022
- Sichenzia Ross Ference LLP Represents ShiftPixy Inc. in a $1.3 Million Warrant Exchange and Exercise - July 20, 2022